Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 10/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786413 | 0.92 | MAPT (0.36) | PTGER1MRGPRX4MAPTCCR5KCNA3 | |
| SCHEMBL21786459 | 0.87 | STIM1 (0.35) | PTGER1MRGPRX4MAPTNPC1GAA | |
| SCHEMBL21786627 | 0.86 | MAPT (0.41) | PTGER1MRGPRX4MAPT | |
| SCHEMBL22791090 | 0.84 | MRGPRX4 (0.36) | PTGER1MRGPRX4MAPTCCR5KCNA3 | |
| SCHEMBL21786412 | 0.83 | MRGPRX4 (0.40) | PTGER1MRGPRX4NPC1CCR5CYP2C9 | |
| SCHEMBL21786622 | 0.82 | MAOB (0.34) | PTGER1MRGPRX4CCR5KCNA3CYP2C9 | |
| SCHEMBL21786448 | 0.81 | CYP11B1 (0.39) | PTGER1CYP2C9 | |
| SCHEMBL21786590 | 0.81 | NPSR1 (0.36) | PTGER1MRGPRX4MAPT | |
| SCHEMBL21786420 | 0.81 | PTPN1 (0.40) | PTGER1MRGPRX4MAPT | |
| SCHEMBL21786446 | 0.81 | PTGER1 (0.40) | PTGER1MAPTCCR5CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | NORTHWESTERN UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | PTGER1 4862/4885MRGPRX4 3150/4885MAPT 3689/4885 |
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | PTGER1 4862/4885MRGPRX4 3150/4885MAPT 3689/4885 |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | MYC, MYCBP, MYCBP2 | PTGER1 4862/4885MRGPRX4 3150/4885MAPT 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.